Andrew Zupnick, PhD

Due to a shifting landscape because of faster drug approvals, this article offers strategies for sponsors to design clinical trials.

Immunotherapy drugs have led to successes in the oncology space as the list of cancer survivors continues to grow. However, more work must be done to ensure that all patients who can benefit from these life-saving drugs receive them.

Successful conduct of hematological malignancy trials requires addressing several unique complexities.

Conducting successful clinical trials in hematological malignancies requires an understanding of a rapidly evolving treatment paradigm that is increasingly nuanced, complex and patient-directed.